

Hindu, Delhi

Friday 25th July 2014, Page: 14

Width: 7.86 cms, Height: 4.80 cms, a4, Ref: pmin.2014-07-25.43.150

Strides Arcolab gets USFDA nod

BANGALORE: Strides Arcolab has received United States Food and Drug Administration (USFDA) approval for Tacrolimus capsules USP 0.5 mg, 1 mg, and 5 mg. The product will be manufactured at its oral dosage facility here, according to a release from the company. It will be marketed directly by Strides in the U.S., where the market for generic Tacrolimus is estimated at \$ 676 million. Tacrolimus capsule is an immunosuppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant, the release adds. — Special Correspondent

Company